Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number

Blood Cancer Journal

Volumn 2, Issue 4, 2012, Pages

  Buors, C ^a,b   Douet Guilbert, N ^a,b,c   Morel, F ^a,b,c   Lecucq, L ^b   Cassinat, B ^d   Ugo, V ^a,b,c  

^a French Blood Agency   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^d SAINT LOUIS HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; JANUS KINASE 2;

ALLELE; BONE MARROW CELL; COPY NUMBER VARIATION; CYTOGENETICS; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; KARYOTYPE; LETTER; MYELOID METAPLASIA; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84864046891     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2012.11     Document Type: Letter

References (14)

1. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22.
2. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 2008; 22: 1299-1307.
3. Tefferi A, Strand JJ, Lasho TL, Knudson RA, Finke CM, Gangat N et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 2007; 21: 2074-2075.
4. Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study. Haematologica 2009; 94: 38-45.
5. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia 2006; 20: 471-476.
6. Fiedler W, Henke RP, Ergun S, Schumacher U, Gehling UM, Vohwinkel G et al. Derivation of a new hematopoietic cell line with endothelial features from a patient with transformed myeloproliferative syndrome: a case report. Cancer 2000; 15: 344-351.
7. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, Tsai S et al. Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979; 54: 713-733.
8. Basel SK. An International System for Human Cytogenetic Nomenclature 2009.
9. De Braekeleer E, Douet-Guilbert N, Basinko A, Morel F, Le Bris M-J et al. Using bacterial artificial chromosomes in leukemia research: the experience at the University Cytogenetics Laboratory in Brest, France. J Biomed Biotechnol 2011; 2011: 329471.
10. Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett 2008; 270: 1-9.
11. Plo I, Nakatake M, Malivert L, de Villartay JP, Giraudier S, Villeval JL et al. JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood 2008; 112: 1402-1412.
12. Nakatake M, Monte-Mor B, Debili N, Casadevall N, Ribrag V, Solary E et al. JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms. Oncogene 2012; 31: 1323-1333.
13. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 2008; 112: 3065-3072.
14. Kuriakose E, Vandris K, Wang YL, Chow W, Jones AV, Christos PJ et al. Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. Haematologica 2011; e-pub ahead of print 18 November 2011; doi:10.3324/haematol.2011.053348.